Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351185 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TRPV6NPC1MEN1KMT2A | |
| SCHEMBL2930850 | 0.87 | TRPV6 (0.53) | ALDH1A1TRPV6NPC1TP53RAB9A | |
| SCHEMBL3869875 | 0.84 | HRH3 (0.55) | ALDH1A1TRPV6KDM4ESMN1; SMN2CYP11B1 | |
| SCHEMBL29725200 | 0.84 | HRH3 (0.55) | ALDH1A1TRPV6KDM4ESMN1; SMN2CYP11B1 | |
| SCHEMBL18937215 | 0.83 | ALDH1A1 (0.54) | ALDH1A1NPC1MEN1KMT2ATP53 | |
| SCHEMBL31093419 | 0.83 | HRH3 (0.59) | ALDH1A1TRPV6KDM4ESMN1; SMN2CYP11B1 | |
| SCHEMBL1858355 | 0.83 | HRH3 (0.59) | ALDH1A1TRPV6KDM4ESMN1; SMN2CYP11B1 | |
| SCHEMBL21550860 | 0.83 | TRPV6 (0.50) | TRPV6MEN1KMT2ACYP11B1ATM | |
| SCHEMBL18823134 | 0.83 | HRH3 (0.53) | ALDH1A1TRPV6MEN1KMT2AKDM4E | |
| SCHEMBL1666554 | 0.81 | ALDH1A1 (0.61) | ALDH1A1NPC1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954659-A | Preparation method of arbeli intermediate | 昊宏(齐河)医药科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119954659-A | Preparation method of arbeli intermediate | 昊宏(齐河)医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-02-13 | — | — | US | disclosed |
| WO-2024167927-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | REVERIE LABS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-04-30 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| CN-117510471-A | Abeli synthesis method | 江苏天士力帝益药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | H. LUNDBECK A/S (DK) | 2016-03-10 | — | — | US | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016014904-A1 | 2-H-INDAZOLE DERIVATIVES AS CYCLIN-DEPENDENT KINASE (CDK) INHIBITORS AND THERAPEUTIC USES THEREOF | BETA PHARMA, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015130540-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2015-09-03 | — | — | WO | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-102264725-A | Protein kinase inhibitors | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2379528-A1 | PROTEIN KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010075074-A1 | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | ALDH1A1 408/4885TRPV6 3960/4885NPC1 561/4885 |
| US-20160068497-A1 | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | HTR2C, DRD2, HTR2A | ALDH1A1 740/4885TRPV6 710/4885NPC1 1545/4885 |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | ALDH1A1 3547/4885TRPV6 3926/4885NPC1 4302/4885 |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | ALDH1A1 4730/4885TRPV6 3306/4885NPC1 2370/4885 |
| US-20250049796-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | CD274, PDCD1LG2, PDCD1 | ALDH1A1 384/4885TRPV6 2228/4885NPC1 2645/4885 |
| US-11970491-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK3 | ALDH1A1 3706/4885TRPV6 3503/4885NPC1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.